Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial assessing EV-D68 for Acute Flaccid Myelitis (AFM)

Next Previous
X
Search
Trial Profile

A trial assessing EV-D68 for Acute Flaccid Myelitis (AFM)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EV D68 (Primary)
  • Indications Acute flaccid myelitis; Myelitis
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Sep 2020 New trial record
    • 07 Sep 2020 According to an Intravacc media release, the company has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top